Allele Biotechnology files lawsuits alleging infringement of mNeonGreen technology

6 October 2020

Privately-held US biotech Allele Biotechnology and Pharmaceuticals has filed two patent infringement lawsuits – one in New York against Regeneron Pharmaceuticals (Nasdaq: REGN) and the other in California against Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).

Both complaints address the infringement of Allele’s patented mNeonGreen technology, an important reagent used in the development of therapeutics for COVID-19.

Allele alleged that the defendants used mNeonGreen in their research without obtaining a license. It said that Pfizer and BioNTech, which have developed the investigational COVID-19 vaccine BNT162, never contacted Allele about obtaining a license, while Regeneron ignored multiple efforts to contact it by Allele.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK